Acrivon Therapeutics, Inc. Common Stock (ACRV NASDAQ) stock market data APIs
$1.5477
0(0%)
as of September 17, 2025
Try our APIs with
free plan!
Acrivon Therapeutics, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.
Prev. Close
1.5477
Open
1.5482
High
1.6709
Low
1.5412
52 wk Range
1.05-8.74
Market Cap
48 756 K
Shares Outstanding
31 456 K
EPS
-0.55
Beta
1.673
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Acrivon Therapeutics, Inc. Common Stock (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Acrivon Therapeutics, Inc. Common Stock data using free add-ons & libraries
Get Acrivon Therapeutics, Inc. Common Stock Fundamental Data
Acrivon Therapeutics, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -93 205 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-13
- EPS/Forecast: -1.09
Get Acrivon Therapeutics, Inc. Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Acrivon Therapeutics, Inc. Common Stock News
New
In today's session, these stocks are experiencing unusual volume.
Let's explore the current happenings on the US markets on Tuesday. Below, you'll find the stocks exhibiting unusual volume in today's session. [unusualvolume] TODAY'S UNUSUAL VOLUME STOCKS TICKE...
Friday's after hours session: top gainers and losers
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. [postmarket] TODAY'S AFTER HOURS GAINERS TICKER CHANGE COMMENT GTBP [http...
JMP reiterates Market Outperform rating on Acrivon Therapeutics stock
Investing.com - JMP Securities has reiterated its Market Outperform rating and $13.00 price target on Acrivon Therapeutics Inc (NASDAQ:ACRV), according to a research note released Friday. The stock, w...
Acrivon Posts Narrower Loss in Q2
Key Points GAAP net loss per share for Q2 2025 was $(0.55), slightly beating the estimated GAAP loss of $(0.57). No product or collaboration revenue was reported as the company remains in clinical de...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
